Xencor announces initial plamotamab Phase 1b data and XmAb657 study update

Xencor announced initial dose-escalation data from its ongoing Phase 1b study of subcutaneous plamotamab, a bispecific CD20 x CD3 T-cell engager, in adults with rheumatoid arthritis, presented at ACR Convergence 2026. The company also provided an update on its first-in-human study for XmAb657.

Detected & updated continuously · Source: Nebula